1,177 results on '"Sanders, Rogier W."'
Search Results
2. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
3. Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
4. Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses
5. A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice
6. Assessing immunogenicity barriers of the HIV-1 envelope trimer
7. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection
8. Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens
9. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual
10. Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates
11. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
12. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies
13. Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens.
14. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
15. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
16. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain
17. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies
18. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
19. Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.
20. Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection
21. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens
22. Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques
23. Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env
24. Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody
25. Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
26. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein
27. Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers
28. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
29. High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers
30. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
31. Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate
32. Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination
33. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
34. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
35. Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses.
36. Gold Nanoparticle Virus-like Particles Presenting SARS-CoV-2 Spike Protein: Synthesis, Biophysical Properties and Immunogenicity in BALB/c Mice.
37. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
38. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
39. Anti-Immune Complex Antibodies are Elicited During Repeated Immunization with HIV Env Immunogens
40. Intramolecular quality control: HIV-1 envelope gp160 signal-peptide cleavage as a functional folding checkpoint
41. Virus vaccines: proteins prefer prolines
42. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
43. Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses
44. Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.
45. Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers
46. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM
47. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
48. A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
49. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles
50. Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.